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Background. Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) has been shown to modulate multiple
cellular processes, including apoptosis. The aim of this study was to assess the effects of HCV NS5A on apoptosis
induced by Toll-like receptor (TLR) 4 ligand, lipopolysaccharide (LPS).
Methods. Apoptotic responses to TLR4 ligands and the expression of molecules involved in TLR signaling
pathways in human hepatocytes were examined with or without expression of HCV NS5A.
Results. HCV NS5A protected HepG2 hepatocytes against LPS-induced apoptosis, an effect linked to reduced
TLR4 expression. A similar downregulation of TLR4 expression was observed in Huh-7–expressing genotype 1b and
2a. In agreement with these findings, NS5A inhibited the expression of numerous genes encoding for molecules
involved in TLR4 signaling, such as CD14, MD-2, myeloid differentiation primary response gene 88, interferon
regulatory factor 3, and nuclear factor–jB2. Consistent with a conferred prosurvival advantage, NS5A diminished
the poly(adenosine diphosphate–ribose) polymerase cleavage and the activation of caspases 3, 7, 8, and 9 and
increased the expression of anti-apoptotic molecules Bcl-2 and c-FLIP.
Conclusions. HCV NS5A downregulates TLR4 signaling and LPS-induced apoptotic pathways in human
hepatocytes, suggesting that disruption of TLR4-mediated apoptosis may play a role in the pathogenesis of HCV
infection.
Hepatitis C virus (HCV), a member of Flaviviridae, is
a causative agent of acute and chronic hepatitis, cirrhosis,
and hepatocellular carcinoma (HCC) [1, 2]. The HCV
genome containing positive-strand RNA is 9.6 kb and
encodes a polyprotein precursor of 3000 amino acids,
which is cleaved by both viral and host proteases into
structural (core, E1, E2, and p7) and nonstructural (NS2,
NS3, NS4A, NS4B, NS5A, and NS5B) proteins. HCV
nonstructural protein 5A (NS5A) exists as 2 phospho-
proteins, p56 and p58, which are both phosphorylated at
serine residues after the mature protein is released from
the polyprotein [3]. Other studies have shown that HCV
NS5A interacts with the proteins of oncogene and in-
terferon (IFN) signaling pathways [4–7].
The immune system provides the first line of host
defenses against microbial pathogens. Toll-like receptors
(TLRs) are type I transmembrane proteins that have
evolved to sense structurally conserved microbial com-
ponents, known as microbial-associated molecular pat-
terns. Thus, TLRs play a primary role in host responses
to infection and in bridging innate and adaptive
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immunity [8, 9]. Thirteen TLRs have been identified in mam-
mals. TLRs 1–9 are conserved between humans and mice. TLR10
is expressed in humans but not in mice, whereas TLRs 11–13 are
present in mice but either absent or nonfunctional in humans.
Activation of intracellular signaling pathways through TLRs is
initiated by the recruitment of adapter proteins, such as myeloid
differentiation primary response gene 88 (MyD88), Toll/in-
terleukin (IL)–1 receptor (TIR) domain–containing adapter
protein (TIRAP)/MyD88 adapter–like, TIR domain–con-
taining adapter-inducing IFN-b (TRIF)/TIR domain–
containing adapter molecule 1, and TRIF-related adapter
molecule to the TIR domain of TLRs. TLR4, primarily located
on the cell surface, is essential for sensing lipopolysaccharide
(LPS) from gram-negative bacteria. Ligand binding to TLR4
stimulates the MyD88-dependent signaling pathway involved
in the production of proinflammatory cytokine genes and the
TRIF-dependent/MyD88-independent signaling pathway, which
is critical for the production of type I IFNs [8]. Interestingly,
concentrations of LPS inducing the production of proin-
flammatory cytokines, such as IL-1b and tumor necrosis factor
(TNF)–a, are similar to those that induce antiviral activity.
Apoptosis is a mode of cell death that disposes of unwanted
cells [10]. Fas ligand and TNF-a are peptide ligands that induce
apoptosis. After Fas ligand binding to its receptor, the cyto-
plasmic domain of the receptor recruits the adapter protein,
Fas-associated death domain–containing protein (FADD), and
the initiator caspase (caspase 8) [11]. Formation of this com-
plex, called the death-inducing signal complex, must be strictly
regulated, because it directly induces activation of the initiator
caspase and apoptotic cascade. The regulation of mitochon-
drial membrane integrity is another important process con-
trolling apoptosis. Mitochondria play an important role in the
activation of apoptosis by releasing apoptogenic factors, such
as cytochrome c, into the cytoplasm. Cytochrome c, caspase 9,
and apoptosis-protease activating factor 1 together form the
apoptosome. Caspase 9 is activated in this complex and sub-
sequently processes executioner caspases 3 and 7. Nuclear
fragmentation and cleavage of poly(adenosine diphosphate–
ribose) polymerase (PARP) are used as apoptotic hallmarks.
Mitochondrial integrity is controlled by the Bcl-2 family of
proteins, such as Bcl-2 and Bcl-XL. Bcl-2 is an anti-apoptotic
protein, blocking cell death via a mitochondria-dependent
pathway.
LPS also induces apoptosis via a death pathway involving
TLR4 signaling. MyD88 subsequently binds FADD, which
promotes activation of caspase 8. These steps are essential for
apoptosis induction [12]. When caspase 8 activation is pre-
vented by anti-apoptotic FLICE-like inhibitory protein (FLIP;
FLICE, FADD-like IL-1-b–converting enzyme), LPS-mediated
apoptosis is blocked. Thus, the apoptotic signaling mechanism
at the cytoplasmic portion of TLR is believed to be similar to
that of the death receptor Fas. However, it was also reported that
disruption of mitochondrial integrity caused by LPS occurs in
a caspase-independent manner [13].
HCV NS5A has been shown to block cell apoptosis in vitro
and in vivo [14, 15]. Taking into account that TLRs modulate
a wide range of cellular functions, including inflammation and
cell proliferation, differentiation, and apoptosis [16, 17], we hy-
pothesized that NS5A influences the TLR4-dependent signaling
pathways and apoptosis.
In the present study, we compared the response of hep-
atocytes expressing or not expressing HCV NS5A to TLR1-7
and TLR9 agonists. We showed that LPS-induced apoptosis
of hepatocytes is inhibited by NS5A. Moreover, NS5A down-
regulates TLR4 expression and proapoptotic pathways in
hepatocytes exposed to LPS. Altogether, our data indicate that
NS5A is a powerful modulator of TLR4 signaling and suggest
that disruption of TLR4-mediated apoptosis may play a role
in the pathogenesis of HCV infection.
METHODS
Plasmids, Cells, and Virus
pCXN2, pCXN2-HCV NS5A, and pCDNA3 and pCDNA3-full-
length human TLR4 vectors were generously provided by J.
Miyazaki (Osaka University), N. Kato (Institute of Medical
Science, Tokyo University), and Scott L. Friedman (Mount Sinai
School of Medicine), respectively. The TLR4 promoter luciferase
reporter vector (2518 construct) was described elsewhere [18].
Human hepatoma cell lines HepG2 and Huh-7 were grown in
Dulbecco’s modified Eagle’s medium (Invitrogen) containing
10% heat-inactivated fetal bovine serum. HepG2 cells were stably
transfected with pCXN2 (HepG2 control cells) or pCXN2-HCV
NS5A genotype 1b (HepG2-NS5A cells). Cells were collected
after 3 weeks of G418 selection, stocked, and used for further
studies. Huh-7 cells harboring HCV subgenomic replicon
genotype 1b and HCV Japanese fulminant hepatitis 1 (JFH1)
genotype 2a were obtained as described elsewhere [19–21].
Treatment of Cells With TLR Ligands
HepG2 control or HepG2-NS5A cells were plated in 6-well
plates and incubated with agonists of TLR1/TLR2 (Pam3CSK4.
3HCL; 100 lg/mL), TLR3 (poly[I:C]; 50 lg/mL), TLR4 (LPS
from Escherichia coli; 5 lg/mL), TLR5 (purified flagellin;
100 lg/mL), TLR6/TLR2 (macrophage-activating lipopeptide
2; 100 lg/mL), TLR7 (Imiquimod [R-837]; 2.5 lg/mL), and
TLR9 (type B CpG ODN; 0.5 lg/mL) (all purchased from
Imgenex). After 24 hours of incubation, cells were fixed for
30 minutes with methanol, washed 3 times with water, air
dried, and stained for 30 minutes with 0.1% crystal violet.
Luciferase Assays
HepG2 cells (5 3 105) were transfected with 0.2 lg of reporter
plasmid pTLR4-luc and pCXN2 or pCXN2-HCV NS5A using
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Effectene (Qiagen). The total amount of DNA was kept constant.
Cells were lysed with reporter lysis buffer (Promega), and lucif-
erase activity was determined by luminometer (Luminescencer-
JNR II AB-2300; ATTO), as described elsewhere [22].
RNA Purification and Real-Time Reverse-Transcription
Polymerase Chain Reaction
Total RNA was isolated using the RNeasy Mini Kit (Qiagen),
and 5 lg of RNA was reverse-transcribed using the First
Strand cDNA Synthesis Kit (SuperArray). Quantitative am-
plification of complementary DNA (cDNA) was monitored
with SYBR Green by real-time polymerase chain reaction
(PCR) analysis. Amplification was carried out in 25 lL of
ROX PCR Master Mix (SuperArray) containing each primer
(0.2 lmol/L) and 1 lL of the reverse-transcription reaction
mixture, using 7300 Real-Time PCR system (Applied Bio-
systems) according to the manufacturer’s protocol. Primers
were purchased from SuperArray. Data analysis was based on
the comparative threshold cycle method. The expression of
the genes of interest was normalized to the expression of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Western Blot Analysis
Cells were harvested using sodium dodecyl sulfate sample
buffer. Proteins were subjected to electrophoresis on 10%
polyacrylamide gels and transferred onto polyvinylidene di-
fluoride membranes (ATTO). Membranes were probed with
antibodies specific for TLR4 (AnaSpec); HCV NS5A and HCV
core protein (Biodesign International); PARP and cleaved
PARP; procaspase 3 and caspases 3, 7, 8, and 9; Bax; Bcl-2;
cellular FLIP (c-FLIP; official name, CFLAR [CASP8 and
FADD-like apoptosis regulator]) (Cell Signalling Technology);
and GAPDH and b-tubulin (Santa Cruz Biotechnology). After
washing, membranes were incubated with secondary horse-
radish peroxidase–conjugated antibodies. Signals were detected
by means of enhanced chemiluminescence (GE Healthcare)
and scanned by image analyzer LAS-1000 and Image Gauge
(version 3.1) (Fuji Film) and Scion Image (Scion) software.
Cell Viability Assay
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) assays were per-
formed (CellTiter 96 AQ One Solution Cell Proliferation Assay;
Promega) [23]; 20 lL/well of the MTS reagent was added to 100
lL of media containing cells in each well of 96-well plates and left
for 4 hours at 37C in a humidified 5% carbon dioxide atmo-
sphere. For analysis, absorbance at 490 nm was measured
using a Bio-Rad iMark microplate reader (Bio-Rad).
Apoptosis Assay
The APOPercentage Apoptosis Assay (Biocolor) was used to
quantify apoptosis according to the manufacturer’s instructions.
Purple-red stained cells were identified as apoptotic cells. The
number of purple-red cells per 300 cells was counted [23].
Enzyme-Linked Immunosorbent Assay
HCV core protein was quantified in HCV-infected cell culture
supernatants with a commercially available enzyme-linked
immunosorbent assay kit (Ortho Diagnostics). The detection
limit was 44 fmol/L.
Statistical Analysis
Results were expressed as means6 standard deviations. Student
t test was used to determine statistical significance.
RESULTS
HCV NS5A and Protection of HepG2 Cells From LPS-Induced
Apoptosis
We and others have previously shown that retinoic acid-
inducible gene I and TLR3 are the 2 major host defense pathways
triggered by HCV in hepatocytes [24, 25]. In contrast, little is
known about the role played by other TLRs in response to HCV
infection [26]. It has been demonstrated that inhibition by HCV
NS5A of TNF-mediated apoptosis may contribute to viral per-
sistence and eventually to HCV-associated disease progression
[4], in a manner similar to that seen with other viruses [27].
Moreover, some TLR ligands induced apoptosis in the liver [28,
29]. To examine the effects of HCV NS5A on TLR signaling in
hepatocytes, we treated HepG2-NS5A and HepG2 control cells
with TLR1-9 ligands and analyzed cell death 24 hours later
(Figure 1A and 1B). Stimulation with LPS (TLR4 ligand) induced
massive death of HepG2 control cells but not HepG2-NS5A cells.
Quantification of apoptosis showed a significant, 3-fold increase
in apoptosis in HepG2 cells, compared with HepG2-NS5A cells
(Figure 1, A and B). Other TLR ligands, sensed through TLR1/2,
TLR2/6, TLR3, TLR5, TLR7, and TLR9, did not significantly
alter the viability of HepG2 control or HepG2-NS5A cells.
HCV NS5A Downregulation of TLR4 Expression in Human
Hepatoma Cell Lines
It has been reported elsewhere that adenovirus infection enhanced
TLR4 expression in wild-type but not in HCV NS5A transgenic
mice [7]. Therefore, we hypothesized that HCV NS5A impaired
TLR4 expression in hepatocytes. To verify this, we compared
TLR4 protein levels in HepG2 and HepG2-NS5A cells. Western
blot analysis showed that TLR4 expression was markedly down-
regulated in HepG2 cells expressing NS5A (Figure 2A).
To further substantiate this observation, we next analyzed
TLR4 expression in HCV subgenomic replicon genotype 1b
and its parental Huh-7 cells [18]. Western blot analyses
demonstrated a significant downregulation of TLR4 expres-
sion along with stable expression of HCV NS5A in replicon
cells (Figure 2B). Finally, Huh-7 cells infected for 3 days with
HCV genotype 2a (JFH1) expressed strongly reduced levels of
TLR4 compared with mock-infected cells (Figure 2C). Con-
firming effective viral replication of JFH1 in Hu-7 cells, cell
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culture supernatants contained 627 fmol/L HCV core protein
3 days after infection (Figure 2D). These data suggested that
HCV NS5A downregulated TLR4 expression in hepatocytes
independently of HCV genotype.
HCV NS5A Inhibition of TLR4 Transcription
To unravel the molecular mechanisms by which NS5A decreased
TLR4 expression in hepatocytes, we first tested whether NS5A
interacted with TLR4. Cell lysates were prepared from HepG2
cells cotransfected with FLAG-tagged NS5A and TLR4 expression
constructs [30], immunoprecipitated with FLAG antibodies, and
probed with TLR4 antibodies. No coprecipitation of TLR4 and
NS5A was detected under our experimental conditions (data not
shown). TLR4 messenger RNA levels, quantified by means of
real-time reverse-transcription PCR, were dramatically reduced
in HepG2-NS5A cells (35-fold), compared with HepG2 cells. In
agreement, transient transfection of HepG2 cells with the pCXN2
HCV NS5A expression plasmid reduced TLR4 promoter driven
luciferase activity (Figure 2E). Overall, these data suggested that
NS5A reduced TLR4 expression, at least in part, by inhibiting
TLR4 transcription in hepatocytes, but not by TLR4 de-
stabilization through direct protein–protein interactions.
HCV NS5A and Expression of Numerous Innate Immune Genes
To further characterize the influence of NS5A on host defense
genes in hepatocytes, we used real-time PCR to quantify the
expression of several genes in HepG2 and HepG2-NS5A cells.
Besides TLR4, NS5A downregulated the expression of molecules
involved in the formation of the TLR4 receptor complex (MD-2
[22-fold] and CD14 [38-fold]) and the expression of down-
stream signaling molecules (MyD88 [.100-fold], nuclear fac-
tor–jB2 [100-fold], and IFN regulatory factor 3 [6.4-fold]).
HCV NS5A and LPS-Induced Apoptosis
It has been reported that the combined effects of HCV and
alcohol on various host cell types, via reactive oxygen species
production, LPS signaling, and cytokine production, produce an
environment of impaired antiviral response, greater hepatocel-
lular injury, and activation of cell proliferation and differentiation
responsible for a range of diseases [31]. Thus, we examined the
effects of LPS with or without ethanol on hepatocytes. Cell trig-
gering through TLR4 has been shown to stimulate apoptotic
signaling pathways [29]. Considering that NS5A sustained sur-
vival of LPS-stimulated HepG2 cells (Figure 1), we investigated
whether NS5A interfered with apoptosis, using Western blot
analysis to detect PARP cleavage and expression of mature cas-
pases 3 and 7. Whereas PARP was expressed at higher levels in
resting HepG2-NS5A cells (1.10 6 0.053 vs 1.0 6 0.026;
P 5 .042), cleavage of PARP induced by LPS with or without
ethanol was observed in HepG2 control cells but was barely
detectable in HepG2-NS5A cells (LPS, 4.57 6 0.65 vs 44 6 1.37
[P , .001]; LPS plus ethanol, 4.71 6 1.13 vs 43.1 6 0.24
[P , .001]) (all n 5 3) (Figure 3A). Accordingly, activation of
procaspase 3 into caspase 3 by LPS with or without ethanol was
strongly reduced in HepG2-NS5A cells versus HepG2 control cells
(LPS, 0.96 6 0.22 vs 3.27 6 0.24 [P , .001]; LPS plus ethanol,
0.936 0.052 vs 3.516 0.29 [P, .001]) and increased expression
of caspase 7 (LPS, 1.21 6 0.18 vs 2.24 6 0.13 [P 5 .0013]; LPS
plus ethanol, 1.15 6 0.20 vs 2.87 6 0.69 [P 5 .014]) (all n 5 3)
(Figure 3B). These data demonstrated that HCV NS5A protected
HepG2 hepatocytes from LPS-induced apoptosis. It has been
reported that LPS may recruit extrinsic apoptotic signals, and
Figure 1. Hepatitis C virus (HCV) nonstructural protein 5 A (NS5A) protects
hepatocytes from lipopolysaccharide (LPS)–induced cell death. A, B, HepG2
control (A) and HepG2-NS5A (B ) hepatocytes were cultured for 24 hours with
ligands of Toll-like receptor (TLR) 1/TLR2 (Pam3CSK4), TLR3 (poly[I:C]), TLR4
(LPS), TLR5 (flagellin), TLR6/TLR2 (macrophage-activating lipopeptide 2),
TLR7 (Imiquimod [R-837]), TLR9 (type B CpG oligonucleotide), and control
oligonucleotide, as indicated in Materials and Methods. Cells were washed
and stained with crystal violet, and experiments were performed 3 times.
PBS, phosphate-buffered saline. C, HCV NS5A protects hepatocytes from
LPS-induced apoptosis. HepG2 control and HepG2-NS5A hepatocytes were
cultured for 24 hours with LPS (5 lg/mL). Cell apoptosis was quantified
using the APOPercentage Apoptosis Assay. Data are expressed as means6
standard deviations of triplicate determinations from 1 experiment represen-
tative of 3 independent experiments.
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alcohol increases liver apoptosis predominantly through intrinsic
signaling [32], but we did not observe a significant difference in
PARP cleavage and the activation of caspases 3 and 7 between LPS
with and LPS without ethanol, suggesting that LPS may also
increase apoptosis through intrinsic signaling in hepatocytes.
HCV NS5A and Expression of Caspases 8 and 9, Bcl-2, and FLIP
Activation of effector caspases 3 and 7 is controlled by caspases
8 and 9, which play a central role in the activation of extrinsic
and intrinsic apoptosis pathways [33]. Interestingly, the ex-
pression levels of both caspases 8 and 9 were decreased in
resting HepG2-NS5A cells and those stimulated by LPS with
or without ethanol versus HepG2 control (caspase 8, 0.72
6 0.013 vs 1.0 6 0.013 [P , .001] and 0.77 6 0.028 vs 1.3
6 0.013 [P, .001] or 0.776 0.013 vs 1.286 0.013 [P, .001])
(caspase 9, 0.71 6 0.035 vs 1.0 6 0.024 [P , .001] and 0.75 6
0.017 vs 1.34 6 0.024 [P , .001] or 0.77 6 0.017 vs 1.35 6
0.010 [P , .001]) (all n 5 3) (Figure 4A). The activation of
caspases 8 and 9 is tightly controlled by regulators, such as
cellular FLICE-like inhibitory protein (c-FLIP), a cellular in-
hibitor of procaspase 8 cleavage into caspase 8, and members
of the Bcl-2 family, including Bax and Bcl-2, which have pro-
and anti-apoptotic activities, respectively [23]. Thus, we in-
vestigated whether NS5A affected the expression of apoptosis
regulators in HepG2 cells. Figure 4B shows the increased levels of
Bcl-2 and c-FLIP in resting HepG2-NS5A cells and those stim-
ulated by LPS with or without ethanol, when compared with
HepG2 cells (Bcl-2, 4.56 0.088 vs 1.06 0.13 [P, .001] and 4.47
6 0.18 vs 1.02 6 0.22 [P , .001] or 4.58 6 0.26 vs 1.0 6 0.30
[P , .001]; c-FLIP [FLIPL plus FLIPS], 1.29 6 0.059 vs 1.0 6
0.059 [P5 .0038] and 1.256 0.049 vs 1.06 0.036 [P5 .0020] or
1.29 6 0.059 vs 1.0 6 0.013 [P 5 .0011]) (all n 5 3).
Overexpression of TLR4 and Apoptosis in HepG2-NS5A Cells
Treated With LPS
We also we chose to overexpress TLR4 to examine whether this
would alter Bcl-2 in HepG2-NS5A cells treated with LPS. First,
we examined cell viabilities 1 day after transient transfection of
pCDNA3 or pCDNA3-full-length human TLR4 vectors into
HepG2-NS5A cells and treatment with 5 lg/mL LPS. Cell via-
bilities of TLR4-overexpressed HepG2-NS5A were reduced,
compared with those of control (74.96 11.4% vs 1006 16.6%;
n 5 4; P 5 .046).
Next, we compared TLR4, cleaved PARP, and Bcl-2 expres-
sion in TLR4-overexpressing LPS-treated HepG2-NS5A cells
with that in control LPS-treated HepG2-NS5A cells. Figure 5
Figure 2. Hepatitis C virus (HCV) nonstructural protein 5A (NS5A)
downregulates Toll-like receptor (TLR) 4 expression in hepatocytes. A–C,
Western blot analyses of TLR4, HCV NS5A, HCV core protein, and GAPDH
expression in HepG2 and HepG2-NS5A cells (A), in HCV subgenomic
replicon genotype 1b and parental Huh-7 cells (B ), and in HCV Japanese
fulminant hepatitis 1 (JFH1) genotype 2a–infected Huh-7 and mock-
infected Huh-7 cells (C ). TLR4/glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) ratios from 3 independent experiments were measured
using Scion Image software. D, HCV core protein concentrations in cell
culture supernatants collected 3 days after infection of Huh-7 cells with
HCV JFH1 were quantified by enzyme-linked immunosorbent assay. No
HCV core protein was detected in cell culture supernatants from mock-
infected cells. E, HepG2 cells were transiently cotransfected with pCXN2
or pCXN2-HCV NS5A and a TLR4 promoter luciferase reporter vector.
Luciferase assays were performed 48 hours after transfection. Data are
expressed as means 6 standard deviations of triplicate determinations
from 1 experiment representative of 3 independent experiments.
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shows the increased levels of TLR4 and PARP in LPS-stimulated
HepG2-NS5A cells transfected with pCDNA3-full-length hu-
man TLR4, compared with those transfected with pcDNA3.
Importantly, Bcl-2 expression was lower in LPS-stimulated
HepG2-NS5A cells transfected with pCDNA3-full-length hu-
man TLR4 than in those transfected with pCDNA3. Therefore,
these results confirmed that NS5A counteracted LPS-induced
apoptosis of hepatocytes by favoring the expression of the anti-
apoptotic signaling molecule Bcl-2.
DISCUSSION
Here we report that downregulation of TLR4 expression by
HCV NS5A is a key step in the negative regulation of LPS-
induced hepatocyte apoptosis. This process negatively influences
TLR4 signaling, including caspase activation and PARP cleavage,
presumably to counteract the deleterious effects of LPS on
hepatocyte viability (Figure 6).
The host defense system against pathogens involves both in-
nate and adaptive immunity. Whereas HCV-specific CD41 and
CD81 T cells are specific for a given antigen, innate immune cells,
such as natural killer and dendritic cells, recognize patterns ex-
pressed by infectious agents, thereby shaping cytokine production
and adaptive immune responses. TLR4 plays an important role in
apoptosis in the liver [34]. The liver is involved at the end of an
immune response, and its cells experience apoptosis, a phenom-
enon that is impaired in mice lacking TLR4 [35]. TLR4 deletion
Figure 3. Hepatitis C virus nonstructural protein 5A (NS5A) inhibits
poly(adenosine diphosphate–ribose) polymerase (PARP) cleavage and
expression of caspases 3 and 7 in HepG2 cells. Western blot analyses
show expression of PARP and cleaved PARP (A) and procaspase 3,
caspase 3, and caspase 7 (B ) in HepG2 control and HepG2-NS5A cells
treated for 24 h with or without lipopolysaccharide (LPS) (5 lg/mL)
and ethanol (100 mmol/L). Blots were reprobed with glyceraldehyde
3-phosphate dehydrogenase (GAPDH)–specific antibodies to assess equal
protein loading. Uncleaved and cleaved PARP/GAPDH ratios (A) and
procaspase 3–GAPDH, caspase 3–GAPDH, and caspase 7–GAPDH ratios
(B ) were measured (all from 3 independent experiments) using Scion
Image software; data are expressed as means 6 standard deviations.
Figure 4. Hepatitis C virus nonstructural protein 5A (NS5A) interferes
with the activation of the apoptotic pathways induced by lipopolysac-
charide (LPS) and ethanol in HepG2 cells. Western blot analyses show
expression of caspases 8 and 9 (A) and Bax, Bcl-2, and FLICE-like
inhibitory protein (FLIP; FLICE, FADD-like IL-1-b–converting enzyme) (B ) in
HepG2 and HepG2-NS5A cells treated for 24 hours with or without LPS (5
lg/mL) and ethanol (100 mmol/L). Blots were reprobed with glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH)–specific antibodies to assess
equal protein loading. Caspase 9/GAPDH and caspase 8/GAPDH ratios (A)
and Bax/GAPDH, Bcl-2/GAPDH and FLIP (FLIPS and FLIPL)/GAPDH ratios
(B ) (all from 3 independent experiments) were measured using Scion
Image software; data are expressed as means 6 standard deviations.
798 d JID 2011:204 (1 September) d Tamura et al
was reported to attenuate pancreatitis-induced mouse liver
cell apoptosis [36] and to reduce ischemia and reperfusion
injury in a murine liver transplantation model [37].
Why does HCV downregulate TLR4 expression by hep-
atocytes? HCV induces a lifelong infection and has evolved
multiple strategies to evade host immune clearance, including
downregulation of major histocompatibility complex class II by
HCV core protein [38], cleavage of IFN promoter stimulator-1
by HCV NS3/NS4A [39], suppression of intrahepatic IFN-c
production by HCV NS5A [7], and inhibition of TNF-mediated
apoptosis by HCV core protein [41] and NS5A [15]. The results
presented here suggest an additional role of HCV NS5A in tar-
geting TLR4 signaling and inhibiting LPS-induced proapoptotic
signals. Our results showing that HCV NS5A downregulated
TLR4 also support an earlier report in macrophage cell lines [6].
Inflammation drives the development of hepatic fibrosis that
leads to cirrhosis in patients with chronic HCV infection. Mul-
tiple variants of the TLR4 gene modulate the risk of liver fibrosis
[30]. Manigold et al [41] reported that TLR4 expression was
downregulated in peripheral blood mononuclear cells of patients
with high serum endotoxin levels at Child-Pugh stage A, irre-
spective of the cirrhosis origin (alcoholic or viral). Machida et al
[42] used transient transfection with plasmids expressing in-
dividual HCV proteins, observing that HCV genotype 1a induced
TLR4 expression in Raji cells and Huh7 cells and increased the
amount of IFN-b and IL-6 with the use of 10 ng/mL LPS, less
than in the present study. Our findings support the previous
report that HCV infection can directly interfere with TLR4 sig-
naling in hepatocytes, peripheral blood mononuclear cells, Raji
cells [42], and dendritic cells [43]. TLR4 signaling itself may
regulate HCV replication [44]. TLR4 missense variants appear to
be associated with the risk of liver fibrosis [45] and other diseases
[46]. HTLV-I p30 also interferes with TLR4 signaling and mod-
ulates the release of pro- and anti-inflammatory cytokines from
human macrophages [47]. These data suggest that TLR4 sig-
naling plays an important role in the pathogenesis of HCV
infection. We also found that upregulation of Bcl-2 and
downregulation of TLR4 is important for blocking LPS-
induced apoptosis in these cells.
Although HCV induced apoptosis as well as the activation of
Bid cleavage and cytochrome c release [48], it remains unknown
whether apoptosis helps in host cell survival or is beneficial for
HCV replication. HCV NS5A may play a fundamental role
during HCV-related HCC development by inhibiting apoptosis.
Further studies will be needed to elucidate the significance of
these results, possibly leading to the development of effective
molecular-targeted treatment against HCC, which is notoriously
resistant to systemic therapies, often recurring even after
aggressive local therapies. Although TLR4 inhibitors are also
now under preclinical and clinical evaluation for the treatment
of sepsis and inflammatory diseases [49], HCV might evade the
innate immune response and also interfere with the adaptive
immune response by functional inactivation of TLR4.
In conclusion, HCV NS5A downregulated TLR4-related sig-
naling pathways and blocked LPS-induced apoptosis in hu-
man hepatocytes, suggesting that it plays an additional
Figure 5. Overexpression of Toll-like receptor (TLR) 4 reduces lipopoly-
saccharide (LPS)–stimulated HepG2-NS5A cell viability. Western blot
analyses of TLR4, cleaved poly(adenosine diphosphate–ribose) polymerase
(PARP), and Bcl-2 expression in pCDNA3 or pCDNA3-full-length human TLR4
(pCDNA3-TLR4)–transfected-HepG2-NS5A cells treated for 24 hours with LPS
(5 lg/mL). Blots were reprobed with tubulin-specific antibodies to assess
equal protein loading. TLR4/tubulin, cleaved PARP/tubulin, and Bcl-2/tubulin
ratios from 3 independent experiments were measured using Scion Image
software; data are expressed as means 6 standard deviations.
Figure 6. Hepatitis C virus (HCV) nonstructural protein 5A (NS5A)
inhibits lipopolysaccharide (LPS)–induced apoptosis in hepatocytes by
downregulating Toll-like receptor (TLR) 4 expression and enhancing Bcl-2
expression, thus impairing activation of initiator (caspases 8 and 9) and
effector (caspases 3 and 7) caspases and downstream signaling, as
shown by reduced poly(adenosine diphosphate–ribose) polymerase
(PARP) cleavage. FADD, Fas-associated death domain–containing protein.
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important role in lasting chronic infection and regulation of
inflammation. The enhancement of TLR4 signaling may have
therapeutic value, and the development of HCV NS5A-targeting
drugs could improve the pathogenesis of HCV infection [50].
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